Spots Global Cancer Trial Database for Study of NMS-1116354 in Solid Tumors
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: Study of NMS-1116354 in Solid Tumors
Official Title: A Phase I Dose-Escalation Study of NMS-1116354 in Adult Patients With Advanced Solid Tumors
Study ID: NCT01016327
Conditions
Interventions
Study Description
Brief Summary: The purpose of this study is to evaluate the safety profile of NMS-1116354, a CDC7 kinase inhibitor, in adult patients with advanced solid tumors.
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
South Texas Accelerated Research Therapeutics (START), San Antonio, Texas, United States
Contact Details
Name: Kyriakos Papadopoulos, MD, MSc
Affiliation: South Texas Accelerated Research Therapeutics (START)
Role: PRINCIPAL_INVESTIGATOR
Name: Bernard Laffranchi, MD
Affiliation: Nerviano Medical Sciences
Role: STUDY_DIRECTOR
Name: Stefania Crippa, Biotech D, PhD
Affiliation: Nerviano Medical Sciences
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
